Kyoto University

Sumitomo Dainippon Pharma Co., Ltd.

Shimadzu Corporation

Ajinomoto Co., Ltd.

Ono Pharmaceutical Co., Ltd.

Umihira Works Co., Ltd.

Junya Toguchida

Tsuyoshi Kobayashi

Tomoki Aoyama

Makoto Ikeya

Kyosuke Hino

Taka-Aki Sato

Sho Senda

Ikue Harata

Makoto Watanabe

Koji Yokoyama

Toshio Heike

Kazuo Umihira

Ryuta Nishikomori

Shunsuke Kawai

Hiroyuki Yoshitomi

Cantas Alev

Hiroki Ozawa

Yonghui Jin

Akira Ohta

The present invention provides a method for inducing osteogenic differentiation, the method comprising the following steps of: (1) culturing pluripotent stem cells under feeder-free conditions, (2) culturing the cells in a mixed culture medium of an osteogenic induction medium and a pluripotent stem cell medium, the mixed culture medium containing a ROCK inhibitor and a retinoic acid receptor α or β agonist, and (3) culturing the cells in an osteogenic induction medium containing the retinoic acid receptor α or β agonist. The method for inducing osteogenic differentiation according to the present invention is a simple, short-term, highly efficient and highly reproducible one-procedure method for inducing osteogenic differentiation, wherein the method is suitable for bone regeneration therapies, the development of bone metabolic drugs and the development of novel therapies for bone diseases.

Method for inducing osteogenic differentiation

Provided is a method of predicting differentiation potential of undifferentiated iPS cells into cartilage cells. Provided is a genetic marker for predicting differentiation potential of undifferentiated iPS cells into cartilage cells. A method of predicting differentiation potential of undifferentiated iPS cells into cartilage cells based on gene expression data of the undifferentiated iPS cells. A method of predicting differentiation potential of undifferentiated iPS cells into cartilage cells by predicting differentiation potential of the iPS cells into neural crest cells (NC cells) based on gene expression data of the undifferentiated iPS cells.

Method of predicting differentiation potential of iPS cells into cartilage cells based on gene expression profiles

The present invention relates to a prophylactic or therapeutic agent for fibrodysplasia ossificans progressiva comprising as an active ingredient, at least one compound selected from the group consisting of rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and pharmaceutically acceptable salts thereof.

Therapeutic agent for fibrodysplasia ossificans progressiva

Mesenchymal stem cells may be culture for a long period, without using any special apparatus, equipment and the like, in a medium in which seven kinds of nonessential amino acids of glycine, alanine, serine, proline, asparagine, aspartic acid, and glutamic acid are reduced.

Culture medium for mesenchymal stem cells

The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.

Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva

A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.

Preventive and therapeutic drug for cartilaginous hyperplasia and method of screening for the same

Growing community of inventors

Kyoto, Japan

Junya Toguchida